Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14829950 | 0.98 | IDO1 (0.53) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25143270 | 0.94 | CYP1A2 (0.51) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29787088 | 0.87 | IDO1 (0.56) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL473578 | 0.87 | IDO1 (0.56) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL28650595 | 0.85 | IDO1 (0.57) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL3591333 | 0.85 | IDO1 (0.57) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5099392 | 0.83 | SIGMAR1 (0.47) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL11621292 | 0.82 | IDO1 (0.65) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6194409 | 0.82 | CHEK1 (0.41) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7988972 | 0.81 | IDO1 (0.54) | IDO1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117442609-A | Application of tetrahydrocarbazole derivative in preventing and treating cow mastitis pathogenic bacteria | 兰州大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117281120-A | Application of tetrahydrocarbazole derivative in preventing and controlling agricultural bacterial diseases | 兰州大学 | 2023-12-26 | — | — | CN | claimed |
| US-9409917-B2 | Heterocyclic amide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-09 | — | — | US | claimed |
| EP-2804865-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-23 | — | — | EP | claimed |
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-01-22 | — | — | US | claimed |
| EP-2804865-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-11-26 | — | — | EP | claimed |
| WO-2013108227-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-25 | — | — | WO | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| EP-1732919-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2006-12-20 | — | — | EP | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| WO-2005095386-A1 | SUBSTITUTED THIOPHENE DERIVATIVES AS ANTI-CANCER AGENTS | CHIRON CORPORATION (US) | 2005-10-13 | — | — | WO | claimed |
| US-20240182420-A1 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | US | disclosed |
| CN-117442609-A | Application of tetrahydrocarbazole derivative in preventing and treating cow mastitis pathogenic bacteria | 兰州大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-117281120-A | Application of tetrahydrocarbazole derivative in preventing and controlling agricultural bacterial diseases | 兰州大学 | 2023-12-26 | — | — | CN | disclosed |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| EP-0525360-B1 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| US-5242944-A | Analgesics or antiinflammatory agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-09-07 | — | — | US | disclosed |
| EP-0525360-A2 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025075-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX3 | IDO1 1408/4885CYP1A2 556/4885CYP3A4 748/4885 |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | IDO1 3135/4885CYP1A2 2356/4885CYP3A4 1562/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | IDO1 1747/4885CYP1A2 35/4885CYP3A4 14/4885 |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | IDO1 2661/4885CYP1A2 1008/4885CYP3A4 3429/4885 |
| US-20240182420-A1 | MICROBIOCIDAL ISONICOTINIC AMIDE DERIVATIVES | ARG2, MPO, ARG1 | IDO1 7/4885CYP1A2 156/4885CYP3A4 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.